Safranal's therapeutic effects in rat models of polycystic ovary syndrome

Basit Öğe Kaydı
dc.contributor.authorCellat, Mustafa
dc.contributor.authorKuzu, Muslum
dc.contributor.authorGuvenc, Mehmet
dc.contributor.authorYuksel, Murat
dc.contributor.authorKanat, Ozgur
dc.contributor.authorBozkurt, Yesim Akaydin
dc.contributor.authorEtyemez, Muhammed
dc.date.accessioned2024-02-23T14:00:14Z
dc.date.available2024-02-23T14:00:14Z
dc.date.issued2023
dc.departmentNEÜen_US
dc.description.abstractPolycystic ovary syndrome is one of the leading causes of female infertility in reproductive age. In this work, the protective effects of safranal against letrozole-induced polycystic ovary syndrome in rats were examined. For this purpose, 32 Wistar albino female rats were split into four groups. Each group received the following treatments for 21 days: Group 1 received carboxymethylcellulose (1%, 2 ml/kg); Group 2, letrozole (1 mg/kg), Group 3, safranal (200 mg/kg); and Group 4 letrozole and safranal via oral gavage. We identified estrus cycles in the rats and analyzed various parameters in their serum and ovarian tissues, as well as histopathologic findings. The parameters studied included C-reactive protein, glucose, total cholesterol, triacylglyceride, high-density lipoprotein, low-density lipoprotein, follicle-stimulating hormone, estradiol, and luteinizing hormone levels in serum. Additionally, the study measured malondialdehyde, glutathione, glutathione peroxidase, and catalase levels in ovarian tissue. We also examined tumor necrosis factor-alpha, interleukin-6, and interleukin-1beta parameters in serum and ovarian tissues, as well as nuclear factor erythroid 2-related factor-2 and heme oxygenase-1 protein levels. In the letrozole group, the estrus cycle was disrupted, and all parameters, except for glutathione and glutathione peroxidase, showed impairments compared to the control group. The findings showed that glucose, triacylglyceride, catalase, and heme oxygenase-1 levels slightly improved after safranal treatment, however, other parameters showed statistically significant improvements. Furthermore, safranal treatment reduced the development of cystic follicles while preserving tissue architecture, as revealed by histopathologic findings. Based on the results obtained, it may be argued that safranal's antioxidant and anti-inflammatory properties, along with its ability to regulate sex hormone levels and manage dyslipidemia, make it a promising solution for patients with polycystic ovary syndrome.en_US
dc.description.sponsorshipScientific Research Projects Coordination Unit of Hatay Mustafa Kemal University [21.A.001]en_US
dc.description.sponsorshipThis study was supported by the Scientific Research Projects Coordination Unit of Hatay Mustafa Kemal University (Grant number 21.A.001en_US
dc.identifier.doi10.1007/s43450-023-00484-6
dc.identifier.issn0102-695X
dc.identifier.issn1981-528X
dc.identifier.scopus2-s2.0-85176798739en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.urihttps://doi.org/10.1007/s43450-023-00484-6
dc.identifier.urihttps://hdl.handle.net/20.500.12452/11521
dc.identifier.wosWOS:001104981900004en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherSpringernatureen_US
dc.relation.ispartofRevista Brasileira De Farmacognosia-Brazilian Journal Of Pharmacognosyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectHyperandrogenismen_US
dc.subjectOxidative Stressen_US
dc.subjectInflammationen_US
dc.subjectPhytochemicalen_US
dc.subjectHerbal Medicineen_US
dc.titleSafranal's therapeutic effects in rat models of polycystic ovary syndromeen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu